New Research Coverage Highlights

NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Overstock.com, Inc. (NASDAQ: OSTK ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ), Molecular Templates Inc. (NASDAQ: MTEM ), The Ensign Group, Inc. (NASDAQ: ENSG ), Limoneira Co (NASDAQ: LMNR ), and Primo Water Corporation (NASDAQ: PRMW ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

OSTK DOWNLOAD: http://Capital-Review.com/register/?so=OSTK REGN DOWNLOAD: http://Capital-Review.com/register/?so=REGN MTEM DOWNLOAD: http://Capital-Review.com/register/?so=MTEM ENSG DOWNLOAD: http://Capital-Review.com/register/?so=ENSG LMNR DOWNLOAD: http://Capital-Review.com/register/?so=LMNR PRMW DOWNLOAD: http://Capital-Review.com/register/?so=PRMW

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Overstock.com, Inc. (NASDAQ: OSTK ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ), Molecular Templates Inc. (NASDAQ: MTEM ), The Ensign Group, Inc. (NASDAQ: ENSG ), Limoneira Co (NASDAQ: LMNR ), and Primo Water Corporation (NASDAQ: PRMW ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 8th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

OVERSTOCK.COM, INC. (OSTK) REPORT OVERVIEW

Overstock's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Overstock reported revenue of $440.58MM vs $424.01MM (up 3.91%) and analysts estimated basic earnings per share -$1.55 vs -$0.03. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Overstock reported revenue of $1,744.76MM vs $1,799.96MM (down 3.07%) and analysts estimated basic earnings per share -$4.28 vs $0.49. Analysts expect earnings to be released on March 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$2.71. The estimated EPS forecast for the next fiscal year is -$2.27 and is expected to report on March 21st, 2019.

To read the full Overstock.com, Inc. (OSTK) report, download it here: http://Capital-Review.com/register/?so=OSTK

-----------------------------------------

REGENERON PHARMACEUTICALS, INC. (REGN) REPORT OVERVIEW

Regeneron Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Regeneron Pharmaceuticals reported revenue of $1,927.80MM vs $1,582.42MM (up 21.83%) and analysts estimated basic earnings per share $7.58 vs $1.61 (up 370.81%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Regeneron Pharmaceuticals reported revenue of $6,710.80MM vs $5,872.20MM (up 14.28%) and analysts estimated basic earnings per share $22.65 vs $11.27 (up 100.98%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $3.98. The estimated EPS forecast for the next fiscal year is $21.11 and is expected to report on February 5th, 2020.

To read the full Regeneron Pharmaceuticals, Inc. (REGN) report, download it here: http://Capital-Review.com/register/?so=REGN

-----------------------------------------

MOLECULAR TEMPLATES INC. (MTEM) REPORT OVERVIEW

Molecular Templates' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Molecular Templates reported revenue of $6.75MM vs $0.65MM (up 941.98%) and analysts estimated basic earnings per share -$0.19 vs -$0.62. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Molecular Templates reported revenue of $3.40MM vs $1.88MM (up 80.59%) and analysts estimated basic earnings per share -$2.11 vs -$59.04. Analysts expect earnings to be released on March 27th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.26. The estimated EPS forecast for the next fiscal year is -$1.14 and is expected to report on March 27th, 2019.

To read the full Molecular Templates Inc. (MTEM) report, download it here: http://Capital-Review.com/register/?so=MTEM

-----------------------------------------

THE ENSIGN GROUP, INC. (ENSG) REPORT OVERVIEW

The Ensign Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, The Ensign Group reported revenue of $537.78MM vs $487.71MM (up 10.27%) and basic earnings per share $0.51 vs $0.21 (up 142.86%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, The Ensign Group reported revenue of $2,040.66MM vs $1,849.32MM (up 10.35%) and analysts estimated basic earnings per share $1.78 vs $0.79 (up 125.32%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.43. The estimated EPS forecast for the next fiscal year is $2.25 and is expected to report on February 5th, 2020.

To read the full The Ensign Group, Inc. (ENSG) report, download it here: http://Capital-Review.com/register/?so=ENSG

-----------------------------------------

LIMONEIRA CO (LMNR) REPORT OVERVIEW

Limoneira's Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, Limoneira reported revenue of $14.71MM vs $15.93MM (down 7.63%) and analysts estimated basic earnings per share -$0.29 vs -$0.19. For the twelve months ended October 31st, 2018 vs October 31st, 2017, Limoneira reported revenue of $129.39MM vs $121.31MM (up 6.66%) and analysts estimated basic earnings per share $1.26 vs $0.42 (up 200.00%). Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending January 31st, 2019. The reported EPS for the same quarter last year was -$0.09. The estimated EPS forecast for the next fiscal year is $1.56 and is expected to report on January 13th, 2020.

To read the full Limoneira Co (LMNR) report, download it here: http://Capital-Review.com/register/?so=LMNR

-----------------------------------------

PRIMO WATER CORPORATION (PRMW) REPORT OVERVIEW

Primo Water's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Primo Water reported revenue of $81.77MM vs $82.21MM (down 0.53%) and analysts estimated basic earnings per share -$1.45 vs $0.15. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Primo Water reported revenue of $286.07MM vs $142.54MM (up 100.70%) and analysts estimated basic earnings per share -$0.19 vs -$0.21. Analysts expect earnings to be released on March 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.02. The estimated EPS forecast for the next fiscal year is $0.49 and is expected to report on March 5th, 2019.

To read the full Primo Water Corporation (PRMW) report, download it here: http://Capital-Review.com/register/?so=PRMW

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Nicole Garrens, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.